| [ 1 ] 张臻,丁小强.血液透析滤过的临床应用进展[J].中国血液净化,2020,19(12):843-846.[ 2 ] 黄盈. 终末期肾病血液透析常见并发症及防护的研究进展[J]. 护理研究,2019,33(5):828-831. [ 3 ] 中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识[J]. 中华肾脏病杂志, 2020, 36(10):781-792.[ 4 ] Yusuf AA, Hu Y, Singh B, et al. Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study [J]. Am J Nephrol .2016; 44(3): 179-86.[ 5 ] Trajceska L, Selim G, Sikole A. Potassium level, malnutrition and mortality in dialysis patients [J]. Int J Artif Organs . 2019;42:426.[ 6 ] Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related metabolic complications [J]. J Am Soc Nephrol . 2009;20(1):164-171. [ 7 ] Hecking E, Bragg-Gresham JL, Rayner HC, et al. Haemodialysis prescription, adherence and nutritional indica tors in five European countries: results from the Dialysis Outcomes and Practice Patterns Study(DOPPS) [J]. Nephrol Dial Transplant, 2004,19(1):100-107.[ 8 ] 赵新菊,牛庆雨,甘良英,等. 基于DOPPS研究分析中国血液透析患者高钾血症的患病率及相关影响因素[J]. 中国血液净化,2021,20(3):145-150,156. [ 9 ] 梅长林,陈晓农,郝传明,等. 慢性肾脏病高钾血症风险评估及管理专家建议（2020版）[J]. 中华医学杂志,2020,100(44):3489-3493.[ 10 ] Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study [J]. Nephrol Dial Transplant . 2018;33(9):1610-1620. [ 11 ] 陶静, 贺倩, 季大玺. 血液透析与高钾血症[J]. 中国基层医药, 2018, 025(008):1080-1084.[ 12 ] Pani A, Floris M, Rosner MH, et al. Hyperkalemia in hemodialysis patients [J] . Seminars in dialysis .2014; 27(6): 571-6.[ 13 ] Kim HJ. Pathogenesis and treatment of dyskalemia in maintenance hemodialysis and CAPD [J] . Electrolyte Blood Press . 2006;4(1):47-52. [ 14 ] 陈笑佟.维持性血液透析患者高钾血症的发生原因与护理对策[J].医疗装备,2017,30(16):146-147.[ 15 ] Bansal S, Pergola PE. Current Management of Hyperkalemia in Patients on Dialysis [J]. Kidney international reports.2020; 5(6): 779-89.[ 16 ] 马丽洁,周亦伦,孙芳,等. 维持性血液透析患者高钾血症的影响因素 [J]. 首都医科大学学报,2009,30(2):150-153. [ 17 ] Bem D, Sugrue D, Wilding B, et al. The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review [J] . Ren Fail. 2021; 43(1): 241-54.[ 18 ] Putcha N, Allon M. Management of hyperkalemia in dialysis patients [J] . Semin Dial. 2007;20(5):431-439. [ 19 ] Weisberg LS. Management of severe hyperkalemia [J] . Crit Care Med. 2008;36(12):3246-3251. [ 20 ] Hwang JC, Wang CT, Chen CA, et al. Hypokalemia is associated with increased mortality rate in chronic hemodialysis patients [J]. Blood Purif. 2011;32(4):254-261. [ 21 ] Alagusundaramoorthy S, Gregory A. Timing is everything: decreasing mortality in severe hyperkalemia [J] . J Am Soc Nephrol. 2018;29:500.[ 22 ] Chatoth D, Wahl P, Rakov V, et al. Real-world outcomes of hyperkalemia management with patiromer in end-stage renal disease patients undergoing hemodialysis in the United States [J] . Nephrol Dial Transplant. 2017;32:iii657.[ 23 ] Karaboyas A, Zee J, Brunelli SM, et al. Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS) [J] . Am J Kidney Dis. 2017;69(2):266-277.[ 24 ] Brunelli SM, Du Mond C, Oestreicher N, et al. Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval [J]. Am J Kidney Dis. 2017;70(1):21-29. |
